<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene F486S literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.F486S</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed striking resistance with only 38% neutralization at the highest concentration tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Highly resistant to mAbs SARS2-07, SARS2-19, 1B07, SARS2-16 and 2B04 of 10 antibodies tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> >60% drop in antibody binding (ELISA) by this variant against monoclonal antibody VH-Fc ab8.<br/> (<a href="https://doi.org/10.1101/2021.03.22.436481" class="lit_link">Sun et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 5 antibodies.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> No effective neutralization in 1 out of the 4 sera tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> IC50 relative to wildtype drops ~8x in neutralization efficiency between 7-17 days post symptoms onset. <br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Modest decrease in in neutralization capability of all 4 convalescent sera tested.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="gene_expression_increase">Gene expression increase</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Experimentally, Spike gene expression increased 0.13 fold (<a href="https://doi.org/10.1016/j.cell.2020.08.012" class="lit_link">Starr et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody (<a href="https://doi.org/10.1016/j.chom.2020.11.007" class="lit_link">Greaney et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
